Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vivus Could File Evamist Menopause Spray By Year-End

This article was originally published in The Pink Sheet Daily

Executive Summary

Transdermal estradiol spray significantly reduces hot flashes in Phase III trial.

You may also be interested in...



Vivus Submits NDA For Skin Spray To Treat Hot Flashs

EvaMist would be marketed as a more convenient form of hormone replacement than oral, gel and patch products.

Vivus Submits NDA For Skin Spray To Treat Hot Flashs

EvaMist would be marketed as a more convenient form of hormone replacement than oral, gel and patch products.

Vivus Evamist Menopause Spray To Start Phase III Under Special Protocol Assessment

Firm will conduct single 12-week trial for treatment of moderate to severe vasomotor symptoms with the transdermal estradiol spray. Evamist would be the first estradiol topical spray formulation, Vivus says.

Related Content

Topics

UsernamePublicRestriction

Register

PS064277

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel